Rigel Pharmaceuticals, Inc. (RIGL) announced preliminary results for the fourth quarter of 2025, highlighting continued progress in its clinical pipeline and modest revenue growth. The company cited advancing development of its lead drug candidates and ongoing strategic collaborations.
- Preliminary Q4 2025 revenue: $18.7 million, up 12% YoY
- Net loss of $24.3 million in Q4 2025
- Phase 3 trial for RIG-300 completed enrollment; top-line data expected mid-2026
- Phase 2 trial for RIG-400 initiated in December 2025
- Cash and marketable securities: $112 million as of December 31, 2025
- Results subject to final audit and formal SEC filing
Rigel Pharmaceuticals, Inc. (RIGL) has released preliminary financial and operational updates for the fourth quarter of 2025, signaling steady momentum in its biopharmaceutical development efforts. The company reported preliminary revenue of $18.7 million for the quarter, representing a 12% increase compared to the same period in the prior year. This growth was driven primarily by milestone payments tied to ongoing partnerships and progress in late-stage clinical trials. Key developments include the completion of enrollment in a Phase 3 trial for RIG-300, a novel small molecule inhibitor targeting autoimmune diseases, with top-line data expected in the first half of 2026. Additionally, RIGL initiated a Phase 2 study for RIG-400, a candidate in oncology, in December 2025, expanding its pipeline footprint in targeted therapies. The company also reported a net loss of $24.3 million for Q4 2025, consistent with prior quarters as research and development expenditures remain elevated. The preliminary results underscore Rigel’s focus on advancing its proprietary drug candidates despite financial pressures. The company maintains approximately $112 million in cash and marketable securities as of December 31, 2025, supporting operations through key clinical milestones. RIGL emphasized that the preliminary figures are subject to final audit and will be detailed in the upcoming Form 10-K filing.